| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | C11; HLP; CCPI; CGL1; CSPB; SECT; CGL-1; CSP-B; CTLA1; CTSGL1 |
| Entrez GeneID | 3002 |
| clone | 2G12G7 |
| WB Predicted band size | 28kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human GZMB (AA: 21-247) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于SF3B3抗体的参考文献示例(内容基于学术文献常见主题构造，非真实文献)：
1. **文献名称**：*SF3B3 Antibody Characterization in Spliceosome Assembly*
**作者**：Johnson A, et al.
**摘要**：本研究利用SF3B3特异性抗体通过免疫共沉淀(Co-IP)和免疫荧光技术，揭示了SF3B3在剪接体动态组装中的关键作用，并验证了抗体在亚细胞定位分析中的可靠性。
2. **文献名称**：*SF3B3 Overexpression in Pancreatic Cancer: A Prognostic Marker*
**作者**：Chen L, et al.
**摘要**：通过Western blot和免疫组化(IHC)分析，发现SF3B3在胰腺癌组织中显著高表达，且与患者生存率降低相关，提示其作为潜在肿瘤标志物的价值。
3. **文献名称**：*Functional Analysis of SF3B3 Mutations via CRISPR and Antibody-Based Detection*
**作者**：Martinez R, et al.
**摘要**：结合CRISPR基因编辑和SF3B3抗体检测，证实SF3B3突变导致异常RNA剪接，并驱动肿瘤发生，为靶向治疗提供理论依据。
4. **文献名称**：*Development of a High-Affinity Monoclonal Antibody Against SF3B3*
**作者**：Wang Y, et al.
**摘要**：报道了一种新型SF3B3单克隆抗体的开发与验证，该抗体在ELISA、流式细胞术及蛋白质印迹中表现出高特异性和灵敏度，适用于基础与临床研究。
(注：以上为示例性内容，实际文献需通过学术数据库检索确认。)
The SF3B3 (Splicing Factor 3B Subunit 3) antibody is a tool used to detect and study the SF3B3 protein, a core component of the spliceosome complex responsible for pre-mRNA splicing. SF3B3 is part of the SF3b complex within U2 small nuclear ribonucleoprotein (snRNP), playing a critical role in recognizing branch site sequences during RNA splicing. This protein is essential for maintaining genomic stability and regulating gene expression.
Antibodies targeting SF3B3 are widely utilized in research to investigate spliceosome assembly, RNA processing mechanisms, and their dysregulation in diseases. Notably, SF3B3 mutations or aberrant expression have been linked to cancers, including hematologic malignancies and solid tumors, making it a potential biomarker or therapeutic target. These antibodies are employed in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP) to analyze SF3B3 expression, localization, and interactions in cellular models or clinical samples.
Commercial SF3B3 antibodies are typically validated for specificity and sensitivity across species (e.g., human, mouse, rat). Researchers often verify results using siRNA knockdown or CRISPR-based gene editing to confirm protein identity. Its study contributes to understanding splicing-related pathologies and developing targeted therapies for splicing factor-mutated cancers.
×
